Citations

Clear

16280 citation(s) found for "Yu, David".

Selective ET A Receptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model
McKenna, Charles J., Burke, Sandra E., Opgenorth, Terry J., Padley, Robert J., Camrud, Ladonna J., Camrud, Allan R., Carlson, Paula J., Holmes, David R. , Schwartz, Robert S., Johnson, Jodi L. , Lerman, Amir

Mayo Clinic

Circulation | June 12, 2012 | Volume: 97 | Issue: 25 | Pages: 2551-2556

10.1161/01.cir.97.25.2551 | PMID 9657476 Get It

Background —As endothelin binds to ET A receptors, it stimulates vascular smooth muscle cell proliferation and may thus be pivotally involved in the pathogenesis of restenosis. This study assessed the ability of a potent and selective ET A antagonist to reduce neointimal hyperplasia in a porcine coronary artery stented injury model. Methods and Results —Fifty-five pigs were randomized to receive placebo or the oral ET A -selective antagonist ABT147627 twice daily for 28 days in one of three doses: 0.75 mg/kg (low), 3.75 mg/kg (mid), and 10.0 mg/kg (high). Each underwent oversized stent deployment in two randomly assigned major epicardial coronary arteries. Three animals (5.5%) died as a consequence of stent thrombosis within 24 hours of the procedure. The remaining 52 animals (13 pigs per group) survived without complication until predetermined euthanasia at 28 days. In the placebo group, mean injury score was 1.73±0.80, with a mean neointimal response of 0.45±0.24 mm. By comparison, the low-dose group had a similar mean injury score of 1.79±0.75 with reduced neointimal response, 0.36±0.22 mm ( P <0.01). Mean injury score in the mid-dose animals was significantly greater than in the placebo group (1.94±0.92; P <0.05). The neointimal hyperplasia associated with this injury was less than with placebo, although the difference did not reach statistical significance (0.40±0.25 mm; P =0.05). In the high-dose pigs, mean injury score was also significantly greater than in the placebo arm (1.93±0.73; P <0.05). Despite this, neointimal response was also significantly less (0.37±0.37 mm; P <0.01). Conclusions —Oral, selective ET A receptor antagonism significantly reduced neointimal hyperplasia forming over porcine coronary stented injuries in the first 28 days. This strategy may have clinical potential for the limitation and treatment of coronary restenosis after percutaneous revascularization.
Dual-Chamber Pacing Is Superior to Ventricular Pacing
Ovsyshcher, E., Hayes, David L. , Furman, S

Mayo Clinic

Circulation | June 12, 2012 | Volume: 97 | Issue: 23 | Pages: 2368-2370

10.1161/01.cir.97.23.2368 | PMID 9639382 Get It

Long-term l -Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans
Burnett, John C. , Higano, Stuart T., McKinley, Linda J., Holmes, David R. , Lerman, Amir

Mayo Clinic

Circulation | June 12, 2012 | Volume: 97 | Issue: 21 | Pages: 2123-2128

10.1161/01.cir.97.21.2123 | PMID 9626172 Get It

Background —Coronary endothelial dysfunction is characterized by an imbalance between endothelium-derived vasodilating and vasoconstricting factors and coronary vasoconstriction in response to the endothelium-dependent vasodilator acetylcholine. Thus, the present double-blind, randomized study was designed to test the hypothesis that long-term, 6-month supplementation of l -arginine, the precursor of the endothelium-derived vasodilator NO, reverses coronary endothelial dysfunction to acetylcholine in humans with nonobstructive coronary artery disease. Methods and Results —Twenty-six patients without significant coronary artery disease on coronary angiography and intravascular ultrasound were blindly randomized to either oral l -arginine or placebo, 3 g TID. Endothelium-dependent coronary blood flow reserve to acetylcholine (10 −6 to 10 −4 mol/L) was assessed at baseline and after 6 months of therapy. There was no difference between the two study groups in clinical characteristics or in the coronary blood flow in the response to acetylcholine at baseline. After 6 months, the coronary blood flow in response to acetylcholine in the subjects who were taking l -arginine increased compared with the placebo group (149±20% versus 6±9%, P <0.05). This was associated with a decrease in plasma endothelin concentrations and an improvement in patients’ symptoms scores in the l -arginine treatment group compared with the placebo group. Conclusions —Long-term oral l -arginine supplementation for 6 months in humans improves coronary small-vessel endothelial function in association with a significant improvement in symptoms and a decrease in plasma endothelin concentrations. This study proposes a role for l -arginine as a therapeutic option for patients with coronary endothelial dysfunction and nonobstructive coronary artery disease.
Prognostic Value of Vasodilator Myocardial Perfusion Imaging in Patients With Left Bundle-Branch Block
Wagdy, Hisham M., Hodge, David O. , Miller, Todd D., Christian, Timothy F. , Gibbons, Raymond J.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 97 | Issue: 16 | Pages: 1563-1570

10.1161/01.cir.97.16.1563 | PMID 9593561 Get It

Background —The prognostic value of tomographic myocardial perfusion imaging with dipyridamole or adenosine in patients with left bundle-branch block has not been established. Methods and Results —The study group consisted of 245 patients with left bundle-branch block who underwent tomographic (single photon emission tomography) myocardial perfusion imaging with thallium-201 (n=173) or technetium-99m sestamibi (n=72) and either dipyridamole (n=153) or adenosine (n=92) stress. Patients were prospectively classified into two groups. Patients were classified as “high risk” if they had (1) a large severe fixed defect (n=28), (2) a large reversible defect (n=36), or (3) cardiac enlargement and either increased pulmonary uptake (thallium) or a decreased resting ejection fraction (sestamibi) (n=20). The remaining 161 patients (66% of the study group) were at “low risk.” Follow-up was 99% complete at 3±1.4 years. Three-year overall survival was 57% in the high-risk group compared with 87% in the low-risk group ( P <.0001). Survival free of cardiac death/nonfatal myocardial infarction/cardiac transplantation was 55% in the high-risk group and 93% in the low-risk group ( P <.0001). The presence of a high-risk scan had significant incremental prognostic value after adjustment for age, sex, diabetes, and previous myocardial infarction ( P <.0001). Patients with a low-risk scan had an overall survival that was not significantly different from that of a US age-matched population ( P =.86). Conclusions —Tomographic myocardial perfusion imaging with adenosine or dipyridamole stress provides important prognostic information in patients with left bundle-branch block, which is incremental to clinical assessment.
A Call for Provisional Stenting
Narins, Craig R. , Holmes, David R. , Topol, Eric J.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 97 | Issue: 13 | Pages: 1298-1305

10.1161/01.cir.97.13.1298 | PMID 9570201 Get It

Myocardial Infarction and Cardiac Mortality in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial
Rosen, Allan D., Williams, David O., Aguirre, Frank V. , Rautaharju, Pentti M., Rogers, William J. , Sharaf, Barry L., Hardison, Regina M., Srivatsa, Sanjay S. , Kouchoukos, Nicholas T. , Detre, Katherine M., Frye, Robert L. , Chaitman, Bernard , Bourassa, Martial G. , Pitt, Bertram , Attubato, Michael , Stocke, Karen S. , Sopko, George S.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 7 | Pages: 2162-2170

10.1161/01.cir.96.7.2162 | PMID 9337185 Get It

Background Cardiac mortality and myocardial infarction (MI) rates are used to evaluate the efficacy of coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA). We compared 5-year cardiac mortality and MI rates in 1829 patients with multivessel disease randomized to CABG or PTCA. Methods and Results The 5-year cardiac mortality rate was 8.0% in patients assigned to PTCA compared with 4.9% in those assigned to CABG (relative risk [RR] of 1.55 with a 95% confidence interval [CI] of 1.07 to 2.23; P =.022). In a subgroup of 1476 nondiabetic patients, there were no significant differences between treatment groups in cardiac mortality either overall (4.6% versus 4.2%; RR=1.04, 95% CI, 0.65 to 1.66; P =.908) or in subgroups based on symptoms, left ventricular function, number of diseased vessels, or stenotic proximal left anterior descending artery. The two treatment groups had similar event rates for the combined end point of cardiac death or MI. The RR for cardiac mortality in 264 patients who sustained an MI compared with those who did not was 5.9 ( P <.001). MIs were more common after CABG during index hospitalization ( P =.004), but in the PTCA group, they were more common after discharge ( P <.001). Conclusions The Bypass Angioplasty Revascularization Investigation (BARI) trial indicates 5-year cardiac mortality in patients with multivessel disease was significantly greater after initial treatment with PTCA than with CABG. The difference was manifest in diabetic patients on drug therapy. There were no significant differences overall for the composite end point of cardiac mortality or MI between treatment groups or for cardiac mortality in nondiabetic patients regardless of symptoms, left ventricular function, number of diseased vessels, or stenotic proximal left anterior descending artery.
Dual-Chamber Pacing in a Patient With Hypertrophic Cardiomyopathy
Symanski, John D. , Hurrell, David G., Nishimura, Rick A.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 5 | Pages: 1701-1701

10.1161/01.cir.96.5.1701 | PMID 9315567 Get It

Predictive Value of Electrophoretically Detected Lipoprotein(a) for Coronary Heart Disease and Cerebrovascular Disease in a Community-Based Cohort of 9936 Men and Women
Nguyen, Tu T., Ellefson, Ralph D., Hodge, David O. , Bailey, Kent R. , Abu-Lebdeh, Haitham S., Kottke, Thomas E.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 5 | Pages: 1390-1397

10.1161/01.cir.96.5.1390 | PMID 9315522 Get It

Background Elevated lipoprotein(a) [Lp(a)] levels have been associated with the presence of atherosclerotic disease. However, the results of prospective studies of Lp(a) and cardiovascular disease have been contradictory. Methods and Results From 1968 through 1982, lipoprotein analysis was performed in 11 335 Olmsted County residents. Quantitative cholesterol and triglycerides were obtained along with semiquantitative Lp(a) levels based on electrophoretic pattern. Lp(a) bands were scored from 0 (absent) to 3 (increased). A cohort of 4967 men and 4968 women with no prior history of atherosclerotic disease who had baseline Lp(a) determinations were followed up for 14 years for development of coronary artery disease (CAD) and cerebrovascular disease (CVD). During 131 330 person-years of follow-up, there were 1848 CAD events and 841 CVD events. Age, diabetes, hypertension, cholesterol, and triglycerides were significantly and independently associated with an increased risk of CAD and CVD in men and women. There was a significant increase in the adjusted hazards ratio for CAD with increasing Lp(a) levels for men and women. For Lp(a) level 3, the hazard ratio was 1.9 (range, 1.3 to 2.9) in women and 1.6 (range, 1.0 to 2.5) in men. The adjusted hazard ratio for CVD showed an irregular association with Lp(a) levels in men and no association in women. Conclusions In this cohort of 9936 men and women initially free of cardiovascular disease who were followed up for 14 years, Lp(a) was a significant predictor of risk of future CAD. Lp(a) was a weak risk factor for CVD in men and was not a significant predictor of CVD risk in women.
Coronary Endothelial Dysfunction in Humans Is Associated With Myocardial Perfusion Defects
Hasdai, David, Holmes, David R. , Higano, Stuart T., Gibbons, Raymond J. , Lerman, Amir

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 10 | Pages: 3390-3395

10.1161/01.cir.96.10.3390 | PMID 9396432 Get It

Background Coronary endothelial dysfunction may occur in patients with minimally obstructive coronary artery disease and angina, and potentially may cause myocardial ischemia. Methods and Results Coronary endothelium-dependent vasodilation was examined in patients with angina and <50% coronary artery diameter (CAD) stenosis by selectively infusing acetylcholine (10 −6 mol/L to 10 −4 mol/L) into the left anterior descending coronary artery (LAD). Percent change in CAD (%ΔCAD) was measured by quantitative coronary angiography, and percent change in coronary blood flow (%ΔCBF) was calculated using intracoronary flow Doppler. Coronary endothelium-independent vasodilation was examined using intracoronary adenosine and nitroglycerin. 99m Tc sestamibi was injected intravenously just prior to the infusion of the highest dose of acetylcholine. Patients were divided blindly into three groups: Perfusion defects in non-LAD territory (group 1, n=6), no perfusion defects (group 2, n=7), and perfusion defects in the LAD territory (group 3, n=7). All patients had intact endothelium-independent vasodilation. In group 1, perfusion defects outside the LAD territory reflected an increase in %ΔCAD and %ΔCBF by 24±5% and 241±46% in the LAD. In group 2, %ΔCAD decreased by 26±5%, but %ΔCBF increased by 54±17%. In group 3, perfusion defects were within the LAD territory, reflecting a decrease in %ΔCAD and %ΔCBF by 35±5% and 51±14%, respectively. Conclusions This study demonstrates that coronary endothelial dysfunction in humans may be temporally associated with myocardial perfusion defects and supports a role for the coronary epicardial and microcirculation endothelium in regulating myocardial perfusion. Myocardial ischemia may occur in humans with impaired endothelium-dependent coronary flow reserve of the coronary epicardial and microcirculation.
Impact of an Aggressive Invasive Catheterization and Revascularization Strategy on Mortality in Patients With Cardiogenic Shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial
Berger, Peter B. , Holmes, David R. , Bates, Eric R., Stebbins, Amanda , Califf, Robert M. , Topol, Eric J.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 96 | Issue: 1 | Pages: 122-127

10.1161/01.cir.96.1.122 | PMID 9236426 Get It

Background Although retrospective analyses have revealed an association between survival and coronary angiography and angioplasty in patients with acute myocardial infarction complicated by cardiogenic shock, the degree to which bias in the selection of patients to undergo these procedures contributes to this observation remains unclear. Methods and Results We studied 2200 patients in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial with acute myocardial infarction complicated by cardiogenic shock (systolic blood pressure <90 mm Hg for ≥1 hour) who survived ≥1 hour after the onset of shock to determine the influence of an aggressive strategy of early angiography (within 24 hours of shock onset) and coronary angioplasty or bypass surgery, if appropriate, on survival. Revascularization was not protocol mandated but was selected by the attending physicians. Shock was present on admission in 11% and developed after admission in 89% of shock patients. The 30-day mortality was 38% in the 406 patients who underwent early angiography and were referred within 24 hours for angioplasty (n=175), bypass surgery (n=36), angioplasty and bypass surgery (n=22), or neither (late or no revascularization, n=173) compared with 62% in the 1794 patients who did not ( P =.0001). However, there were important differences in the baseline characteristics of the two groups, including younger age (63 versus 68 years, P =.0001), less prior infarction (19% versus 27%, P =.001), and a shorter time to thrombolytic therapy (2.9 versus 3.2 hours, P =.0001) in patients treated with an aggressive strategy. Using multivariate logistic regression analysis to adjust for differences in baseline characteristics, an aggressive strategy was independently associated with reduced 30-day mortality (odds ratio, 0.43 [confidence interval, 0.34 to 0.54], P =.0001). Conclusions An aggressive strategy of early angiography (and revascularization when appropriate) is associated with a reduction in mortality in patients with acute myocardial infarction and cardiogenic shock who receive thrombolytic therapy.